Overview

• Investors of BioVie Inc. face a March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action.
• The lawsuit alleges BioVie and its executives violated federal securities laws by making false and/or misleading statements regarding its Phase 3 clinical trial.
• BioVie's share price fell more than 60% following the disclosure of significant deviations from protocol and Good Clinical Practice violations in its clinical trial.
• Multiple law firms are encouraging BioVie investors to secure counsel before the important March 19 deadline.
• The class action seeks to recover losses for BioVie investors who were adversely affected between August 5, 2021, and November 29, 2023.